Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

734.81
-23.4600-3.09%
Post-market: 736.801.99+0.27%19:51 EDT
Volume:1.04M
Turnover:770.25M
Market Cap:75.65B
PE:18.17
High:777.43
Open:766.53
Low:726.02
Close:758.27
52wk High:859.34
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:1.30
T/O Rate:1.05%
Dividend:3.64
Dividend Rate:0.50%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.39
PE(LYR):17.71

Loading ...

Sanofi Exec Says "There is no Certainty at This Point in Time, but We are Actively Working in Order to Extend the Loss of Exclusivity of Dupixent"

THOMSON REUTERS
·
Yesterday

Sanofi CEO Says Expects the Market for Atopic Dermatitis Treatments to Nearly Double over the Next Five Years -Conf Call

THOMSON REUTERS
·
Yesterday

Argus Upgrades Regeneron Pharmaceuticals to Buy From Hold, Price Target is $850

MT Newswires Live
·
Yesterday

Regeneron Pharmaceuticals, Inc. : Argus Research Raises to Buy from Hold

THOMSON REUTERS
·
Yesterday

Stocks to Watch: Micron, Alphabet, Sanofi, Nu Holdings

Dow Jones
·
Yesterday

Sanofi’s Regeneron Fix Requires Extra Shot of M&A

Reuters
·
Yesterday

Sanofi CEO Takes First Step Toward Addressing Long-Term Outlook

Dow Jones
·
Yesterday

Sanofi to Get Pipeline Boost from Expanded Regeneron Alliance

Dow Jones
·
Yesterday

Sanofi, Regeneron Expand Tie-up with $8 Billion Drug-Development Deal, Settle Legal Dispute

Reuters
·
Yesterday

Regeneron, Sanofi Expand Antibody Alliance with USD 1 Billion Upfront Payment

Reuters
·
Yesterday

Sanofi, Regeneron Expand Antibody Alliance in Long-Acting Immunology Programs for USD 1 Billion Upfront

Reuters
·
Yesterday

Sanofi - Companies to Equally Share Development and Commercialization Costs, as Well as Any Future Profits

THOMSON REUTERS
·
Yesterday

Sanofi - and Regeneron Settle Prior Collaboration-Related Litigation

THOMSON REUTERS
·
Yesterday

Sanofi - Regeneron May Include Sanofi's Lunsekimig Therapy After Phase 3 Studies

THOMSON REUTERS
·
Yesterday

Sanofi - Regeneron to Receive $1 Bln Upfront with Potential for up to an Additional $7 Bln in Future Milestone Payments

THOMSON REUTERS
·
Yesterday

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Yesterday

Regeneron Drug Halves Muscle Loss in Combination with Novo's Semaglutide in Trial

Reuters
·
Yesterday

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Yesterday

Regeneron Links 2026 CEO, CSO PSU Awards to FDA Filings, Approvals and New-Product Revenue Targets Through 2035

Reuters
·
Yesterday

Regeneron’s ALN-F1202 Safety Trial Marks a Quiet but Important Pipeline Milestone

TIPRANKS
·
Yesterday